These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22517899)

  • 1. SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.
    Reddy PN; Sargin B; Choudhary C; Stein S; Grez M; Müller-Tidow C; Berdel WE; Serve H; Brandts CH;
    Blood; 2012 Aug; 120(8):1691-702. PubMed ID: 22517899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation mechanisms of STAT5 by oncogenic Flt3-ITD.
    Choudhary C; Brandts C; Schwable J; Tickenbrock L; Sargin B; Ueker A; Böhmer FD; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2007 Jul; 110(1):370-4. PubMed ID: 17356133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
    Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
    Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
    Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
    Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.
    Nakajima H; Shibata F; Kumagai H; Shimoda K; Kitamura T
    Int J Hematol; 2006 Jul; 84(1):54-9. PubMed ID: 16867903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
    Wallace JA; Kagele DA; Eiring AM; Kim CN; Hu R; Runtsch MC; Alexander M; Huffaker TB; Lee SH; Patel AB; Mosbruger TL; Voth WP; Rao DS; Miles RR; Round JL; Deininger MW; O'Connell RM
    Blood; 2017 Jun; 129(23):3074-3086. PubMed ID: 28432220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA; Kazi JU; Rönnstrand L
    Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.
    Kresinsky A; Schnöder TM; Jacobsen ID; Rauner M; Hofbauer LC; Ast V; König R; Hoffmann B; Svensson CM; Figge MT; Hilger I; Heidel FH; Böhmer FD; Müller JP
    Oncogene; 2019 Jun; 38(24):4773-4787. PubMed ID: 30820040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.
    Kellner F; Keil A; Schindler K; Tschongov T; Hünninger K; Loercher H; Rhein P; Böhmer SA; Böhmer FD; Müller JP
    J Cell Mol Med; 2020 Apr; 24(8):4668-4676. PubMed ID: 32155324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
    Kelly LM; Liu Q; Kutok JL; Williams IR; Boulton CL; Gilliland DG
    Blood; 2002 Jan; 99(1):310-8. PubMed ID: 11756186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment.
    Demirel Ö; Balló O; Reddy PNG; Vakhrusheva O; Zhang J; Eichler A; Fernandes R; Badura S; Serve H; Brandts C
    PLoS One; 2017; 12(7):e0180401. PubMed ID: 28753604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
    Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
    Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
    Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
    Elife; 2016 Nov; 5():. PubMed ID: 27879203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
    Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D
    Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
    Lee BH; Williams IR; Anastasiadou E; Boulton CL; Joseph SW; Amaral SM; Curley DP; Duclos N; Huntly BJ; Fabbro D; Griffin JD; Gilliland DG
    Oncogene; 2005 Nov; 24(53):7882-92. PubMed ID: 16116483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
    Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
    Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation.
    Marhäll A; Kazi JU; Rönnstrand L
    Sci Rep; 2017 Oct; 7(1):13734. PubMed ID: 29062038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells.
    Abe M; Pelus LM; Singh P; Hirade T; Onishi C; Purevsuren J; Taketani T; Yamaguchi S; Fukuda S
    PLoS One; 2016; 11(7):e0158290. PubMed ID: 27387666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.